Failure patterns in resected pancreas adenocarcinoma: Lack of predicted benefit to SMAD4 expression

Annals of Surgery

Volumn 258, Issue 2, 2013, Pages 331-335

  Winter, Jordan M ^a   Tang, Laura H ^b   Klimstra, David S ^b   Liu, Weiguo ^b   Linkov, Irena ^b   Brennan, Murray F ^b   DêAngelica, Michael I ^b   Dematteo, Ronald P ^b   Fong, Yuman ^b   Jarnagin, William R ^b   OêReilly, Eileen M ^b   Allen, Peter J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

distal pancreatectomy; pancreas; pancreas cancer; pancreaticoduodenectomy; recurrence pattern; SMAD4

Indexed keywords

ANTINEOPLASTIC AGENT; SMAD4 PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DEATH; DISTANT METASTASIS; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TREATMENT FAILURE;

CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; SMAD4 PROTEIN; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880573095     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827fe9ce     Document Type: Article

References (19)

1. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495.
2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
4. Latil A, Bièche I, Cĥene L, et al. Gene expression profiling in clinically localized prostate cancer: A four-gene expression model predicts clinical behavior. Clin Cancer Res. 2003;9:5477-5485.
5. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
6. Takeno A, Takemasa I, Seno S, et al. Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol. 2010;17:1033-1042.
7. Yoshioka S, Takemasa I, Nagano H, et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer. 2009;45:881-889.
8. Wang DY, Done SJ, McCready DR, et al. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res. 2011;13:R92.
9. Crane CH,VaradhacharyGR,Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostainingwith pattern of disease progression. J Clin Oncol. 2011;29:3037-3043.
10. Iacobuzio-Donahue CA, FuB,Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
11. Winter JM, Tang LH, Klimstra DS, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012;7(7):e40157.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
13. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci U S A. 1998;95:2412-2416.
14. Winter JM, Maitra A, Yeo CJ. Genetics and pathology of pancreatic cancer. HPB (Oxford). 2006;8:324-336.
15. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
16. Hilgers W, Su GH, Groot Koerkamp B, et al. Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning. Genes Chromosomes Cancer. 1999;25:370-375.
17. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674-4679.
18. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002;20:4531-4542.
19. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol. 2012;19:169-175.